Violations of chemotherapy protocols for ovarian cancer - Reasons and consequences;Verletzungen des therapieplans und des chemotherapieprotokolls beim ovarialkarzinom - Grunde und konsequenzen

Zentralblatt fur Gynakologie

Volumn 120, Issue 11, 1998, Pages 534-539

  Munstedt K ^a,c   Hering, K ^a   Prittwitz, J V ^a   Zygmunt, M ^a   Franke, F E ^b   Vahrson, H ^a  

^a Abt Gyakologische Onkologie u S

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Chemotherapy; Dose intensity; Ovarian cancer; Protocol violations; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; DOSE RESPONSE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; OVARY CANCER; THROMBOCYTE COUNT; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 0031740755     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ackermann S, Jäger W, Merkle E, Martus P, Lang N: Highdose vs. lowdose cisplatinum plus treosulfan chemotherapy in advanced ovarian cancer: results of a randomized trial (abstract # 1274). Proc Am Soc Clin Oncol 16 (1997) 358a
2. Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K et al: Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 4 (1993) Suppl., 83-88
3. Blum RH, Frei E, Holland JF: Principles of dose, schedule, and combination chemotherapy. In: Cancer Medicine. Eds.: Holland JF, Frei E, Blum RH. 1982, 730-752
4. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. J Am Med Assoc 273 (1995) 542-547
5. Bronchud M: Can haematopoietic growth factors be used to improve the success of cytotoxic chemotherapy. Anti Cancer Drugs 4 (1993) 127-139
6. De Vita VT: Principles of chemotherapy. In: Cancer - Principles & Practise of Oncology, Eds.: DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott 1993, 276-292
7. Druckrey H, Steinhoff D, Nakayama M, Preussmann R, Anger K: Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan. Dtsch Med Wochenschr 88 (1963) 715-721
8. Fanning J, Bennett TZ, Hilgers RD: Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian cancer. Obstet Gynecol 80 (1992) 954-960
9. Hurwitz HI, McGuire WP: Primary chemotherapy in epithelial ovarian cancer. Obstet Gynecol Clin North Am 21 (1994) 141-154
10. Karthaus M, Ganser A: Derzeitiger Stand der klinischen Anwednung von hämatopoetischen Wachstumsfaktoren nach Chemo-/Strahlentherapie in der Gynäkologie. Zentralbl Gynakol 119 (1997), 585-596
11. Levin L, Hryniuk W: The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Sem Oncol 14 (1987) 12-19
12. Levin L, Hryniuk W: Dose intensity analysis of chemotherapy in ovarian cancer. J Clin Oncol 5 (1987) 756-767
13. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EF, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
14. Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M, Patel U, Dougal M, Buckley CH, Tindall VR: A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 4 (1993) 377-383
15. Ozols RF, Rubin SC, Thomas G, Robboy S: Epithelial ovarian cancer. In: Principles and Practise in Gynecologic Oncology. Eds.: Hoskins WJ, Perez CA, Young RC. Philadelphia: Lippincott Raven 1997, 919-986
16. Rustin GJS, Gennings JN, Nelstrop AE, Covaaubias H, Lambert HE, Bagshawe KD: Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 7 (1989) 1667-1671
17. Sorbe B, Helsing M: The prognostic importance of myelo-suppression in the response to chemotherapy and survival in advanced ovarian carcinoma. Cancer 59 (1987) 690-694
18. Skipper HE: Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res 27 (1967) 2636-2645
19. Tokuhashi Y, Kikkawa F, Ishikawa H, Tamakoshi K, Hattori S, Matsuzawa K, Inoue T, Suganuma N, Tomoda Y: Distribution of platinum in human gynecologic tissue and pelvic lymph nodes after administration of cisplatin. Gynecol Obstet Invest 44 (1997), 270-274
20. de Vries EGE, Biesma B, Willemse PHB, Mulder NH, Stern AC, Aalders JG, Vallenga E: A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51 (1991) 116-122